Urology Research & Practice
Original Article

Long-acting liposomal bupivacaine decreases inpatient narcotic requirements in men undergoing penile prosthesis implantation


Division of Urology, UC San Diego Health System, San Diego, California, USA


Division of Urology, Albany Medical Center, Albany, NY, USA


Department of Radiology, Aurora St Luke Medical Center, Milwaukee, Wisconsin, USA


Division of Urology, Southern Illinois University School of Medicine, Springfield, Illinois, USA

Urol Res Pract 2016; 42: 230-234
DOI: 10.5152/tud.2016.44442
Read: 1547 Downloads: 777 Published: 25 July 2019


Objective: A new extended-release bupivacaine suspension bupivacaine (ERSB) delivers 3 days of local anesthetic and has been shown to reduce pain and narcotic usage in some patient groups but this issue is largely unstudied in urologic surgery.


Material and methods: We performed a single-surgeon retrospective chart review of the patients who underwent penile prosthesis implantation. Pain scores and standardized morphine equivalent (ME) dose data were collected during 23 hour-observation period. Subjects who received ERSB were compared with those who received standard bupivacaine or no local anesthesia.


Results: In a study population of 37 patients, those who received (n=13), and did not receive (n=24) ERSB were grouped, respectively. The groups were comparable demographically. ME was used 3.2 fold more frequently in the non-ERSB group (18.0, and 5.6 for non-ERSB, and ESRB groups, respectively (p=0.04). Mean overall pain scores were 3.8/10 for ERSB and 3.9/10 for non-ERSB group, respectively. Per patient medication cost for the control, and ERSB groups were $5.16 and $285.54, respectively.


Conclusion: The use of a new ERSB in penile prosthesis implants did lead to reduced narcotic consumption with comparable postoperative pain control to the non-ERSB group. However, the cost of the ERSB ($285/dose) may be prohibitive for its use. 

EISSN 2980-1478